Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
© The Author 2015. Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals r...
محفوظ في:
المؤلفون الرئيسيون: | Anthony T. Podany, Yajing Bao, Susan Swindells, Richard E. Chaisson, Janet W. Andersen, Thando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Constance A. Benson, Peter Kim, Courtney V. Fletcher |
---|---|
التنسيق: | دورية |
منشور في: |
2018
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84943232683&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/54683 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
المؤسسة: | Chiang Mai University |
مواد مشابهة
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
بواسطة: Anthony T. Podany, وآخرون
منشور في: (2018) -
One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis
بواسطة: Susan Swindells, وآخرون
منشور في: (2019) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
بواسطة: Jyoti S. Mathad, وآخرون
منشور في: (2022) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
بواسطة: Mathad J.S.
منشور في: (2023) -
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens
بواسطة: Nontiya Homkham, وآخرون
منشور في: (2018)